Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
1.
Lupus ; 33(4): 340-346, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38334100

RESUMO

BACKGROUND: Systemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort. METHODS: Patients were from a multi-ethnic, multi-national Latin-American SLE inception cohort. All participating centers had specialized lupus clinics. Socio-demographic, clinical/laboratory, disease activity, damage, and mortality between those with a longer and a shorter time to diagnosis were compared using descriptive statistical tests. Multivariable Cox regression models with damage accrual and mortality as the end points were performed, adjusting for age at SLE diagnosis, gender, ethnicity, level of education, and highest dose of prednisone for damage accrual, plus highest dose of prednisone, baseline SLEDAI, and baseline SDI for mortality. RESULTS: Of the 1437 included in these analyses, the median time to diagnosis was 6.0 months (Q1-Q3 2.4-16.2); in 721 (50.2%) the time to diagnosis was longer than 6 months. Patients whose diagnosis took longer than 6 months were more frequently female, older at diagnosis, of Mestizo ethnicity, not having medical insurance, and having "non-classic" SLE symptoms. Longer time to diagnosis had no impact on either damage accrual (HR 1.09, 95% CI 0.93-1.28, p = 0.300) or mortality (HR 1.37, 95% CI 0.88-2.12, p = 0.200). CONCLUSIONS: In this inception cohort, a maximum time of 24 months with a median of 6 months to SLE diagnosis had no apparent negative impact on disease outcomes (damage accrual and mortality).


Assuntos
Lúpus Eritematoso Sistêmico , Feminino , Humanos , Progressão da Doença , Hispânico ou Latino , América Latina/epidemiologia , Lúpus Eritematoso Sistêmico/diagnóstico , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Lúpus Eritematoso Sistêmico/complicações , Prednisona/uso terapêutico , Índice de Gravidade de Doença , Masculino
2.
Lupus ; 33(3): 282-288, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38237938

RESUMO

OBJECTIVE: To identify all post-BNT162b2 vaccination (BioNTech and Pfizer) events during the ensuing 12 months in patients with systemic lupus erythematosus (SLE) from the Immuno-Rheumatology Department at Cayetano Heredia Hospital's cohort, Lima, Perú. METHODS: A 12-month follow-up study was conducted from the first dose of immunization with the BNT162b2 vaccine, which was given between May and June 2021, to SLE patients from this cohort. RESULTS: The initial population was constituted by 100 patients (100 patients received the 1st dose, 90 the 2nd dose, and 85 the 3rd dose of this vaccine); 33 patients presented a SLE reactivation (flare), 9% (9/100) post 1st dose, 26.6% (24/90) post 2nd dose, and 16.4% (14/85) post 3rd dose. The most common types of flare were articular (26) and renal (14) with 5/33 (15.1%) requiring hospitalization for flare management. A negative association with flare occurrence was found between the use of hydroxychloroquine RR 0.43 (0.21-0.85) and the opposite was the case for azathioprine RR 2.70 (1.39-5.25). During follow-up, 26 patients developed SARS-CoV-2 infection of whom three required hospitalization, one of whom died. CONCLUSIONS: 33 of 100 SLE patients immunized with BNT162b2 vaccine against SARS-CoV-2, presented SLE flares (47 episodes in total); 5 of these patients required in-hospital management and all fully recovered; 26 patients had SARS-CoV-2 infection; three required hospitalization, one died.


Assuntos
COVID-19 , Lúpus Eritematoso Sistêmico , Humanos , Vacina BNT162 , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19/administração & dosagem , Seguimentos , Imunização , Lúpus Eritematoso Sistêmico/tratamento farmacológico , SARS-CoV-2 , Vacinação
3.
Clin Rheumatol ; 41(5): 1349-1357, 2022 May.
Artigo em Inglês | MEDLINE | ID: mdl-34782941

RESUMO

The objective of this study is to identify post SARS-CoV-2 vaccine BNT162b2 (BioNTech & Pfizer) side effects in patients with systemic lupus erythematosus (SLE) at the Cayetano Heredia Hospital, Lima, Peru. A descriptive observational study was designed in patients with SLE at the Immuno-Rheumatology Department of the Cayetano Heredia Hospital, Lima, Peru, immunized with the BNT162b2 vaccine from May 21 to June 30, 2021. Of the total number of patients seen in the service, 100 received the vaccine's 1st dose, and 90 patients received the 2nd dose; 90% and 92.2% presented symptoms within 10 days after immunization (1st and 2nd doses, respectively), being pain at the inoculation site the most frequent (87%); most of the symptoms presented were of mild intensity. There were 27 episodes of post-immunization flare, 9% and 20% after the 1st and 2nd doses, respectively; the predominant type of flare was articular (85.1%), followed by dermal (18.5%). It was found that a history of renal involvement was associated with the risk of developing flare RR 0.38 (0.15-0.91) and the use of hydroxychloroquine and azathioprine prior to immunization 0.20 (0.06-0.63) and 7.96 (2.70-23.43) respectively. In 100 SLE patients immunized with BNT162b2 vaccine against SARS-CoV-2, 27% of SLE reactivation episodes occurred, two patients were hospitalized for flare severity, and none died. Key Points • Up to 92.2% presented some type of symptom after vaccination, being mostly local and of mild intensity. • Of the population studied, there were 27 episodes of post-vaccination flare, most of which were mild. • In the studied population, taking hydroxychloroquine and having a history of renal disease were associated with a lower risk of presenting post-vaccination flare.


Assuntos
COVID-19 , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Lúpus Eritematoso Sistêmico , Vacinas , Vacina BNT162 , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/etiologia , Humanos , Hidroxicloroquina , Lúpus Eritematoso Sistêmico/complicações , SARS-CoV-2 , Vacinação/efeitos adversos
9.
Braz. j. otorhinolaryngol. (Impr.) ; Braz. j. otorhinolaryngol. (Impr.);86(3): 300-307, May-June 2020. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1132606

RESUMO

Abstract Introduction: Otomycosis, an infection of the ear canal by fungi, is prevalent in hot and humid weather. Nevertheless, there is not sufficient evidence for the effectiveness of different topical antifungal treatments. Tolnaftate, is a topical antifungal agent described to be effective in the treatment of otomycosis. Currently there are not sufficient studies that prove its efficacy. Objectives: To compare the efficacy of clotrimazole and tolnaftate administration in the treatment of otomycosis. Material and methods: A controlled, randomized and open clinical trial included patients diagnosed with fungal external otitis who were treated with topical antifungals, randomized into two treatment groups: (1) clotrimazole cream; (2) tolnaftate solution. They were microscopically evaluated at one and two weeks of treatment to determine resolution of disease. Recurrence and complications were recorded. Demographic and clinical variables were collected and analyzed. Follow-up and final outcomes (absence of infection) were compared between groups. Results: Forty eight patients were included, 28 in the clotrimazole group and 20 in the tolnaftate group. Spring was the weather most commonly associated with otomycosis, while otic manipulation was the risk factor more common in both groups. Predominant symptoms were itching and otic fullness. Aspergillus niger organism was isolated most frequently. Treatment with clotrimazole resulted in 75% resolution vs 45% resolution with treatment with tolnaftate at one week of treatment (p = 0.007). The Tolnaftate treatment group demonstrated higher recurrence rates and treatment failures, 20% and 15% respectively. Conclusions: Clotrimazole cream treatment is more effective than tolnaftate for uncomplicated otomycosis. More studies are needed to corroborate our results.


Resumo Introdução: Otomicose, uma infecção fúngica do canal auditivo externo, é prevalente em climas quentes e úmidos. No entanto, a literatura não apresenta evidências suficientes sobre os diferentes tratamentos antifúngicos tópicos. O tolnaftato é um antifúngico tópico descrito como eficaz no tratamento da otomicose; entretanto, sua eficácia não está suficientemente comprovada. Objetivo: Comparar a eficácia do uso de clotrimazol e tolnaftato no tratamento da otomicose. Material e método: Ensaio clínico controlado e randomizado; incluiu pacientes diagnosticados com otite externa fúngica tratados com antifúngicos tópicos, randomizados em dois grupos de tratamento: 1) clotrimazole (creme); 2) solução de tolnaftato. Eles foram avaliados microscopicamente uma e duas semanas após o início do tratamento para avaliar a resolução da doença. Recorrência e intercorrências foram registradas; além disso, as variáveis demográficas e clínicas foram coletadas e analisadas. Os dados do acompanhamento e desfechos finais (ausência de infecção) foram comparados entre os grupos. Resultados: O estudo incluiu 48 pacientes, 28 dos quais foram alocados ao grupo clotrimazole e 20 ao grupo tolnaftato. A primavera foi a estação mais comum; a manipulação foi o fator de risco mais comum em ambos os grupos. Os sintomas mais comuns foram coceira e plenitude auricular. Aspergillus niger foi o micro-organismo mais comumente isolado. Após uma semana, o tratamento com clotrimazol apresentou uma taxa de resolução de 75% vs. 45% com o tratamento com tolnaftato (p = 0,007). O tratamento com tolnaftato apresentou maiores taxas de recidiva e falhas: 20% e 15%, respectivamente. Conclusões: Em casos de otomicose não complicada, o uso de clotrimazol (creme) é mais eficaz do que o de tolnaftato. Mais estudos são necessários para corroborar os presentes resultados.


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Adulto Jovem , Tolnaftato/administração & dosagem , Clotrimazol/administração & dosagem , Otomicose/tratamento farmacológico , Antifúngicos/administração & dosagem , Resultado do Tratamento , Otomicose/microbiologia
10.
Braz J Otorhinolaryngol ; 86(3): 300-307, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-30826311

RESUMO

INTRODUCTION: Otomycosis, an infection of the ear canal by fungi, is prevalent in hot and humid weather. Nevertheless, there is not sufficient evidence for the effectiveness of different topical antifungal treatments. Tolnaftate, is a topical antifungal agent described to be effective in the treatment of otomycosis. Currently there are not sufficient studies that prove its efficacy. OBJECTIVES: To compare the efficacy of clotrimazole and tolnaftate administration in the treatment of otomycosis. MATERIAL AND METHODS: A controlled, randomized and open clinical trial included patients diagnosed with fungal external otitis who were treated with topical antifungals, randomized into two treatment groups: (1) clotrimazole cream; (2) tolnaftate solution. They were microscopically evaluated at one and two weeks of treatment to determine resolution of disease. Recurrence and complications were recorded. Demographic and clinical variables were collected and analyzed. Follow-up and final outcomes (absence of infection) were compared between groups. RESULTS: Forty eight patients were included, 28 in the clotrimazole group and 20 in the tolnaftate group. Spring was the weather most commonly associated with otomycosis, while otic manipulation was the risk factor more common in both groups. Predominant symptoms were itching and otic fullness. Aspergillus niger organism was isolated most frequently. Treatment with clotrimazole resulted in 75% resolution vs 45% resolution with treatment with tolnaftate at one week of treatment (p=0.007). The Tolnaftate treatment group demonstrated higher recurrence rates and treatment failures, 20% and 15% respectively. CONCLUSIONS: Clotrimazole cream treatment is more effective than tolnaftate for uncomplicated otomycosis. More studies are needed to corroborate our results.


Assuntos
Antifúngicos/administração & dosagem , Clotrimazol/administração & dosagem , Otomicose/tratamento farmacológico , Tolnaftato/administração & dosagem , Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Otomicose/microbiologia , Resultado do Tratamento , Adulto Jovem
13.
Comunidad salud ; 15(1): 9-19, jun. 2017. ilus
Artigo em Espanhol | LILACS | ID: biblio-890943

RESUMO

La leptospirosis es una antropozoonosis de distribución mundial, con mayor incidencia en países tropicales. En Venezuela los casos son registrados en el sistema nacional de vigilancia para enfermedades íctero-hemorrágicas, con poca publicación sobre los aspectos clínicos y epidemiológicos de la enfermedad, por lo tanto el objetivo fue establecer las características epidemiológicas, clínicas, y diagnósticas de la leptospirosis en el Estado Aragua. El diseño fue un estudio epidemiológico transversal que describe los casos confirmados y probables de leptospirosis, obtenidos a partir del programa nacional de Síndrome Febril Ictérico Hemorrágico. Como resultados de 533 casos reportados desde enero del 2011 hasta julio del 2013, 233 (43,7%) fueron probables y 68 (12,75%) confirmados de leptospirosis. La tasa cruda de incidencia acumulada de leptospirosis por 100.000 habitantes más elevada en el periodo de estudio ocurrió en el año 2012, con un valor de 2,94 y los municipios con mayor tasa fueron Bolívar (7,9) y Sucre (5,2). Los factores de riesgo más reportados fueron: presencia de roedores en vivienda con 63,2%, marzo y abril, los meses con menor pluviosidad presentaron la menor frecuencia de casos. Los síntomas más frecuentes en los casos confirmados fueron fiebre 75%, cefalea 61,8%, ictericia 55,9%, vómitos 54,4%, dolor abdominal 47,1%, diarrea 35,3%. Cefalea, artralgia, mialgia y dolor retro-ocular predominaron en mayores a 10 años. 12,8% de los casos de leptospirosis se diagnosticaron por PCR en sangre, 28% PCR en orina, 45,2% por MAT.


Leptospirosis is a worldwide distribution anthropozoonosis, with a higher incidence in tropical countries. In Venezuela, the cases are registered in the national surveillance system for the ictero-hemorrhagic diseases, with little documentation upon clinical and epidemiological aspects of the disease; hence, the aim of this study was to establish epidemiologic, clinical and diagnostic characteristics of leptospirosis in Aragua state. It was a Cross sectional epidemiological study where probable and confirmed cases of leptospirosis were described, obtained from the febril icterohemorrhagic national surveillance program. From 533 cases reported since January of 2011 to July of 2013, 233 (43,79%) were probable cases, 68 (12,75%) were confirmed for leptospirosis. The highest cumulative incidence crude rate of leptospirosis per 100.000 inhabitants of the study period occurred in 2012 with 2,94. Bolivar (7,9%) and Sucre (5,2%) were the municipalities with the highest incidence rate. The main risk factors were: the presence of rodents in houses 63,2%, march and april were the months with the lowest rainfall which showed the fewest number of cases. The most frequent symptoms in confirmed cases were fever (75%), headaches (61,8%), jaundice (55,9%), vomiting (54,4%), abdominal pain (47,1%), diarrhea (35,3%), were the most frequent symptoms among confirmed cases. Headache, joint pain, myalgia, and retroocular pain, were significantly more frequent in ages over 10 years. 12,8% of the caseswere diagnosed by PCR based on blood, 28% by PCR based on urine, 45,2% by MAT.

14.
Rev Peru Med Exp Salud Publica ; 33(1): 162-7, 2016 Mar.
Artigo em Espanhol | MEDLINE | ID: mdl-27384637

RESUMO

A 55-year-old female patient, born in Ayacucho, with a history of dermatomyositis for 3 years, who received irregular treatment with prednisone. Two months prior to admission, she presented with autoinmune hemolytic anemia and idiopathic thrombocytopenic purpura. The patient received methylprednisolone pulse therapy and packed red blood cells transfusions. Upon admission, she was drowsy, with a poor overall status, marked weight loss, dehydration, with presence of livedo reticularis in her lower extremities, and onychodystrophy and onycholysis on the toes of both feet. Western blot test was positive for human T-lymphotropic virus type 1 (HTLV-1). The patient evolved with recurrent hypoglycemia. Therefore, we report a case of dermatomyositis and Evans syndrome in the context of an HTLV-1 infection.


Assuntos
Anemia Hemolítica Autoimune/diagnóstico , Infecções por HTLV-I/complicações , Trombocitopenia/diagnóstico , Anemia Hemolítica Autoimune/complicações , Feminino , Humanos , Pessoa de Meia-Idade , Púrpura Trombocitopênica Idiopática , Trombocitopenia/complicações
16.
Rev. peru. med. exp. salud publica ; 33(1): 162-167, ene.-mar. 2016. ilus
Artigo em Espanhol | LILACS, LIPECS, INS-PERU | ID: lil-790824

RESUMO

Paciente mujer de 55 años de edad, natural de Ayacucho, con antecedente de dermatomiositis desde hace 3 años, recibió tratamiento irregular con prednisona. Dos meses antes del ingreso presenta anemia hemolítica autoinmune y púrpura trombocitopénica idiopática, recibió pulsos de metilprednisolona y transfusión de paquetes globulares. Al ingreso, soporosa, mal estado general, marcada pérdida ponderal, deshidratada, livedo reticularis en miembros inferiores, onicodistrofia y onicolisis múltiple en los dedos de ambos pies. Western Blot positivo para HTLV-1. Evoluciona con hipoglicemia recurrente. Reportamos un caso de dermatomiositis y síndrome de Evans presentados en el contexto de una infección por virus linfotrópico humano tipo 1...


A 55-year-old female patient, born in Ayacucho, with a history of dermatomyositis for 3 years, who received irregular treatment with prednisone. Two months prior to admission, she presented with autoinmune hemolytic anemia and idiopathic thrombocytopenic purpura. The patient received methylprednisolone pulse therapy and packed red blood cells transfusions. Upon admission, she was drowsy, with a poor overall status, marked weight loss, dehydration, with presence of livedo reticularis in her lower extremities, and onychodystrophy and onycholysis on the toes of both feet. Western blot test was positive for human T-lymphotropic virus type 1 (HTLV-1). The patient evolved with recurrent hypoglycemia. Therefore, we report a case of dermatomyositis and Evans syndrome in the context of an HTLV-1 infection...


Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Anemia Hemolítica Autoimune , Dermatomiosite , Infecções por HTLV-I , Vírus Linfotrópico T Tipo 1 Humano , América Latina
18.
Rev. Soc. Peru. Med. Interna ; 27(4): 181-185, oct.-dic.2014. ilus
Artigo em Espanhol | LILACS, LIPECS | ID: lil-781652

RESUMO

El pénfigo foliáceo endémico (P F E) o fuego salvaje es una dermatosis ampollar auto inmune presente en áreas de la Amazonia peruana. Se caracteriza por vesículas intraepidérmicas acantolíticas, localizadas en la región subcorneal y en cuya etiología participan anticuerpos contra desmogleína 1, una glicoproteína encargada de la unión intercelular de las células epidérmicas. Se presenta el caso de en una mujer de 52 años con PFE grave, de evolución fulminante y desenlace fatal por sepsis...


The endemic pemphigus foliaceus (EPF) or fogo selvagem is an autoimmune bullous dermatosis located in areas of our Amazon jungle .It is characterized by intraepidermic acantholytic vesicles in the subcorneal region and its etiology involves the presence of antibodies to desmoglein 1, a glycoprotein responsible for the intercellular junctions of the epidermal cells. We present the case of a 52-year-old woman with severe PFE with fulminant evolution and fatal outcome due to sepsis...


Assuntos
Humanos , Pessoa de Meia-Idade , Pênfigo , Pênfigo/diagnóstico , Pênfigo/terapia
20.
Acta méd. peru ; 31(4): 213-219, oct.-dic. 2014. ilus, tab
Artigo em Espanhol | LILACS, LIPECS | ID: lil-735440

RESUMO

Introducción. Estudios preclínicos evidencian efectos dosis dependiente sobre la analgesia e inflamación y neurotoxicidad de las hojas, corteza y raíz de J. curcas L. El propósito del estudio fue evaluar la actividad analgésica y neurofarmacológica de las fracciones de la semilla de J. curcas L. Métodos. Estudio experimental, preclínico y prospectivo. Se distribuyeron 48 ratones en seis grupos control: ácido acético, diclofenaco, tramadol, agua destilada, diazepam y cafeína. Cuatro grupos experimentales: fracción soluble a 500 mg/kg y fracción no soluble a 250, 500 y 750 mg/kg; se evaluó los efectos sobre la algesia, por medio de la prueba de contorsiones abdominales por ácido acético a 1,5 %, y las manifestaciones neurológicas, mediante la prueba de Irwin. Se realizaron pruebas para el análisis de las variables cuantitativas y para las variables cualitativas. Resultados. La inhibición de las contorsiones fue 62,27 %, 56,86 %, 44,12 % y 42,06 % para los grupos 5, 2, 4 y 3, respectivamente. Las manifestaciones neurológicas de los grupos experimentales mostraron presencia y significancia de las variables excitación, sacudidas de cabeza, rascarse, incoordinación motora, cola de Straub, piloerección y estereotipias. Las variables estereotipias y rascado se presentaron en las dos fracciones. Conclusión. La fracción soluble y la no soluble del extracto etanólico de J. curcas L. presentaron efecto analgésico y efectos tóxicos a nivel del sistema nervioso central.


Introduction. Preclinical studies show the dose dependent effects on the analgesia, inflammation and neurotoxicity of the leaves, bark and root. The purpose of the study was to evaluate the analgesic and neuropharmacological activity of the fractions of the seed J. curcas L. Methods. Experimental study, preclinical and prospective. 48 rats were distributed in 6 control groups: acetic acid, diclofenac, tramadol, distilled water, diazepam, caffeine. Four experimental groups: 500 mg/kg of soluble fraction and 250, 500 y 750 mg/kg of insoluble fraction; the effects on the algesia were evaluated using an exam of abdominal contortions with acetic acid on 1,5%; the neurological manifestations were measured with the Irwin test. To analyze the quantitative and qualitative variables exams were used. Results. The inhibition of the contortions were 62,27 %, 56,86 %, 44,12 % y 42,06 % for the groups 5, 2, 4 y 3, respectively. The neurological manifestations of the experimental groups showed the presence and significance of the variables: excitation, head twitches, scratching, motor incoordination, Straub tail, piloerection and stereotypies. The variables stereotypes and scratching presented themselves in the two fractions. Conclusion. The soluble and insoluble fraction of the ethanoic extract of J. Curcas L. presented analgesic and toxic effects on the central nervous system.


Assuntos
Jatropha/toxicidade , Jatropha/uso terapêutico , Sistema Nervoso Central
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA